Published in Can J Infect Dis on November 01, 1997
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 6.84
Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med (1995) 6.56
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 6.25
The changing epidemiology of cystic fibrosis. J Pediatr (1993) 5.50
Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A (1988) 3.83
Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med (1996) 3.82
Defective acidification of intracellular organelles in cystic fibrosis. Nature (1991) 3.66
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science (1996) 3.38
Pathogenesis of cystic fibrosis. Lancet (1993) 3.34
Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest (1993) 3.00
Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract. Infect Immun (1983) 2.86
Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med (1996) 2.80
Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr (1986) 2.38
Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro. Infect Immun (1995) 2.27
Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ (1995) 2.12
The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol (1976) 2.09
Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A (1995) 1.97
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis (1991) 1.84
Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis (1990) 1.81
Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrob Agents Chemother (1989) 1.69
Production of the Pseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression. J Clin Invest (1992) 1.58
Viscosity versus composition in airway pathology. Am J Respir Crit Care Med (1994) 1.44
Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.44
Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet (1993) 1.42
Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr (1995) 1.40
Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr (1980) 1.34
Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa. Surv Synth Pathol Res (1985) 1.25
Biochemistry of airway mucus secretions. Fed Proc (1980) 1.25
Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr (1984) 1.16
Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis (1995) 1.13
Human tracheobronchial mucin: purification and binding to Pseudomonas aeruginosa. Infect Immun (1992) 1.10
Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Paediatr Scand (1986) 1.07
Nonopsonic phagocytosis of Pseudomonas aeruginosa requires facilitated transport of D-glucose by macrophages. J Immunol (1995) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Beat frequency of cilia from sites of purulent infection. Thorax (1986) 1.03
Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr (1987) 1.00
Defective acidification of the biosynthetic pathway in cystic fibrosis. J Cell Sci Suppl (1993) 1.00
Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest (1993) 1.00
Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system. Pediatr Pulmonol (1991) 0.98
Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child (1980) 0.97
Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol (1993) 0.94
Cystic fibrosis: beyond the gene to therapy. J Pediatr (1992) 0.89
Evaluation of mist tent therapy in cystic fibrosis using maximum expiratory flow volume curve. Pediatrics (1972) 0.88
The effect of sublethal levels of antibiotics on the pathogenicity of Pseudomonas aeruginosa for tracheal tissue. J Antimicrob Chemother (1987) 0.85
Bronchiectasis in childhood. Pediatr Clin North Am (1984) 0.83
Renal clearance of gentamicin in cystic fibrosis. J Pediatr (1983) 0.82
The experimental production of bronchiectasis in rats. J Pathol Bacteriol (1954) 0.81
Cystic fibrosis. Pediatr Rev (1994) 0.80